Market Access:
essential step to provide innovative healthcare solutions to patients
To obtain optimal reimbursement/price conditions for both primary care and hospital is a key to facilitate the integration of innovations into the patient pathway. A in-depth understanding of the challenges of market access, budgetary constraints, the national and international environment, and the role of the various players is essential.
- Our sectoral expertise
A dedicated team working with all healthcare stakeholders, combining a deep understanding of the public and private (institutional and political) ecosystem.
Nextep’s proven approach stands out for its ability to assess the ecosystem and capture stakeholder expectations.
A “patient-first” approach, built on understanding our clients’ needs and providing personalized, hands-on support.
Our expertise draws on experience, a trusted network of experts, analytical insight, benchmarking, and PLG’s global one-stop-shop model.
Our consulting activities are strengthened by a truly global scope of action.
Our Areas of Intervention
European and National Market Access Strategy
Nextep designs tailored strategies for market access and reimbursement in Europe, integrating regulatory, pricing, and local priority considerations, with a detailed country-by-country roadmap.
Clinical Evidence Generation, Real-World Data & New Data Collection Methodologies
- Early Advice & European JSC: Nextep facilitates early advice and joint scientific committees to optimize your market access strategies in Europe.
- Clinical Trial Management: We coordinate your clinical trials from start to finish, ensuring actionable evidence for your value dossier and reimbursement access.
- Synthetic Data: With BOT Design, we use AI to create artificial cohorts, accelerating clinical studies and enhancing scientific validation, even for rare diseases.
- Real-World Data: We collect and analyze real-world data to demonstrate the medico-economic and organizational impacts, optimizing your reimbursement access in France and Europe.
Clinical and Economic Evaluation & Reimbursement Access in France and Europe
- Early/Exceptional/Transitional Reimbursement Access: Nextep evaluates your technology’s eligibility and drafts your HAS dossiers to expedite its early access, regardless of its development stage.
- Standard Reimbursement Access: We build a strong argument and draft your complete dossiers to demonstrate clinical benefit and optimize your reimbursement pricing.
- Medico-Economic Data and CEESP Evaluations: We conduct efficiency studies and economic models to quantify your solution’s impact, strengthen negotiations, and support scientific publications.
- EU JCA and Global Value Dossiers: Nextep prepares your global value dossiers and aligns your data with the requirements of the European Joint Clinical Assessment (EU JCA) to facilitate access to international markets.
Price Negotiation, New Contractualization Methods, and Stakeholder Engagement
- Support for Economic Negotiations with the Payer: Nextep supports your negotiations with the CEPS, building a solid argument and counter-proposals based on competitive analysis to optimize your pricing.
- New Contractualization Models: We model innovative pricing scenarios with the CEPS, integrating real-world data and validated indicators to value your breakthrough technologies while ensuring the sustainability of the system.
- Establishment of a Payer Board and Strategic Analysis: We bring together experts to anticipate payer expectations, refine your medico-economic positioning, and define a consistent long-term access strategy, including at the European level.
- Target Product Profile: Nextep develops a precise target product profile aligned with payer requirements and clinical needs, to maximize the value of your technology from its development.
